Welcome to BioSeeker Group!

Competitive Handbook towards Personalized Medicine in Prostate Cancer

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1493
PDF Fact Sheet View Fact Sheet for the report Competitive Handbook towards Personalized Medicine in Prostate Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Competitive Handbook towards Personalized Medicine in Prostate Cancer.

    To find out more about Competitive Handbook towards Personalized Medicine in Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Competitive Handbook towards Personalized Medicine in Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, compound types and companies are setting the path?

* How much R&D effort has gone towards different targets and what is known about the target?

* Which pathways are targeted, by what and how?

* What is truly new and unique in the prostate cancer pipeline?

* How new and unique your target strategy really is

* What overlapping competition you have from other companies and compound types towards your therapeutic targets

* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:

1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4. Company: Provides a cross-examination of each company’s entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:
* Head-to-head target competing analysis

* Significant drug target overlap analysis

* Cross-sectional R&D profiling of individual drug targets.

* Cross-over analysis of target strategies among different compound types.

* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company’s pipeline:
- Where are we?
- Where is our general and specific competition?
- What is the level of competition where we want to be?
- 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company’s interest in the prostate cancer pipeline by:
* Better identifying benchmarking peers

* Providing rationale for in/out licensing decisions of drug candidates

* Performing proper drug due diligence

* Strategies for commercial planning

* Guiding Research & Development efforts

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 22
4.2 List of Tables 22
5 Introduction 31
5.1 The Scope of this Report 31
5.2 Definitions 34
5.3 Abbreviations 34
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 35
6.1 Drug Repositioning in Oncology 35
6.2 Introduction to Targets of Prostate Cancer Drugs 36
6.2.1 Acid Phosphatase Activity Targets 45
6.2.2 Auxiliary Transport Protein Activity Targets 46
6.2.3 Calcium Ion Binding Targets 47
6.2.4 Carboxy-lyase Activity Targets 48
6.2.5 Carboxypeptidase Activity Targets 49
6.2.6 Catalytic Activity Targets 51
6.2.7 Cell Adhesion Molecule Activity Targets 68
6.2.8 Chaperone Activity Targets 76
6.2.9 Chemokine Activity Targets 80
6.2.10 Complement Activity Targets 82
6.2.11 Cysteine-type Peptidase Activity Targets 85
6.2.12 Cytokine Activity Targets 88
6.2.13 DNA Binding Targets 96
6.2.14 DNA Repair Protein Targets 97
6.2.15 DNA Topoisomerase Activity Targets 98
6.2.16 DNA-directed DNA Polymerase Activity Targets 102
6.2.17 Extracellular Ligand-gated Ion Channel Activity Targets 107
6.2.18 Extracellular Matrix Structural Constituent Targets 109
6.2.19 G-protein Coupled Receptor Activity Targets 111
6.2.20 Growth Factor Activity Targets 121
6.2.21 GTPase Activator Activity Targets 130
6.2.22 Hormone Activity Targets 131
6.2.23 Hydrolase Activity Targets 132
6.2.24 Intracellular Ligand-gated Ion Channel Activity Targets 133
6.2.25 Ion Channel Activity Targets 134
6.2.26 Isomerase Activity Targets 135
6.2.27 Kinase Activity Targets 136
6.2.28 Ligand-dependent Nuclear Receptor Activity Targets 144
6.2.29 Ligase Activity Targets 147
6.2.30 Lipid Kinase Activity Targets 152
6.2.31 Lipid Phosphatase Activity Targets 158
6.2.32 Metallopeptidase Activity Targets 159
6.2.33 MHC Class I Receptor Activity Targets 162
6.2.34 Molecular Function Unknown Targets 163
6.2.35 Motor Activity Targets 173
6.2.36 Oxidoreductase Activity Targets 175
6.2.37 Peptidase Activity Targets 181
6.2.38 Peptide Hormone Targets 187
6.2.39 Peroxidase Activity Targets 188
6.2.40 Phosphoric Diester Hydrolase Activity Targets 189
6.2.41 Protein Binding Targets 191
6.2.42 Protein Serine/Threonine Kinase Activity Targets 194
6.2.43 Protein Tyrosine Phosphatase Activity Targets 222
6.2.44 Protein-tyrosine Kinase Activity Targets 229
6.2.45 Receptor Activity Targets 242
6.2.46 Receptor Binding Targets 262
6.2.47 Receptor Signaling Complex Scaffold Activity Targets 265
6.2.48 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 271
6.2.49 RNA Binding Targets 273
6.2.50 RNA-directed DNA Polymerase Activity Targets 274
6.2.51 Serine-type Peptidase Activity Targets 275
6.2.52 Structural Constituent of Cytoskeleton Targets 280
6.2.53 Superoxide Dismutase Activity Targets 282
6.2.54 Transcription Factor Activity Targets 286
6.2.55 Transcription Regulator Activity Targets 303
6.2.56 Transferase Activity Targets 310
6.2.57 Translation Regulator Activity Targets 311
6.2.58 Transmembrane Receptor Activity Targets 315
6.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 320
6.2.60 Transporter Activity Targets 351
6.2.61 Ubiquitin-specific Protease Activity Targets 355
6.2.62 Voltage-gated Ion Channel Activity Targets 357
6.2.63 Other Targets 358
6.3 Mutation Profiles of Prostate Cancer Drug Targets 360
6.3.1 Targets of Prostate Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 360
6.4 Prostate Cancer Therapeutics is Stimulated by Available Structure Data on Targets 366
6.5 Target-Target Interactions among Identified Targets of Prostate Cancer Drugs 370
6.6 The Drug-Target Competitive Landscape 374
6.7 Protein Expression Levels of Identified Targets of Prostate Cancer Drugs 379
6.8 Pathway Assessment of Prostate Cancer Drugs 382
6.8.1 Tools for Analysis of Cancer Pathways 383
6.8.2 Pathway Assessment 384
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development 438
7.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Prostate Cancer Drugs 441
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs 443
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs 445
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs 451
7.5 Preclinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs 454
7.6 Drug Target Strategies of Suspended or Terminated Prostate Cancer Drugs 457
7.7 Target Strategy Development Profiles of Prostate Cancer Drugs 461
7.7.1 Marketed 466
7.7.2 Pre-registration 479
7.7.3 Phase III 480
7.7.4 Phase II 496
7.7.5 Phase I 573
7.7.6 Preclinical 607
7.7.7 No Data 635
7.7.8 Suspended 637
7.7.9 Ceased 641
7.8 The Competition Through Close Mechanistic Approximation of Prostate Cancer Drugs 690
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy 700
8.1 Small Molecules 702
8.1.1 Background 702
8.1.2 Target Strategies of Small Molecule Drugs 703
8.2 Peptide & Protein Drugs 717
8.2.1 Background 717
8.2.2 Target Strategies of Peptide and Protein Drugs 718
8.3 Antibodies 725
8.3.1 Background 725
8.3.2 Target Strategies of Antibody Drugs 725
8.4 Nucleic Acid Therapies 729
8.4.1 Background 729
8.4.2 Target Strategies of Nucleic Acid Drugs 730
8.5 Cell & Gene Therapy 733
8.5.1 Background 733
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 734
8.6 Drug Delivery and Nanotechnology 738
8.6.1 Background 738
8.6.2 Target Strategies of Reformulated Drugs 738
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 741
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator 749
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 754
9.2 Company Facts and Ranking 757
9.3 Competitive Fall-Out Assessment 764
9.4 Abbott 766
9.5 Active Biotech 771
9.6 Advantagene 773
9.7 AEgera 775
9.8 AEterna Zentaris 777
9.9 Alchemia 779
9.10 Alethia Biotherapeutics 782
9.11 Allos Therapeutics 784
9.12 AlphaVax 786
9.13 Alseres Pharmaceuticals 788
9.14 Altor BioScience 792
9.15 Ambrilia Biopharma 794
9.16 American Gene Technology International 799
9.17 Amgen 801
9.18 Anavex Life Sciences 806
9.19 AndroBioSys 808
9.20 Antisense Pharma 811
9.21 Antisense Therapeutics 813
9.22 Antisoma 816
9.23 Aphios 820
9.24 ApopLogic Pharmaceuticals 823
9.25 Apotex 825
9.26 Aprea 827
9.27 Ardana 829
9.28 Ariad 834
9.29 ArQule 837
9.30 Array BioPharma 839
9.31 Ascenta Therapeutics 841
9.32 Ascepion Pharmaceuticals 843
9.33 Astellas 845
9.34 Astex Pharmaceuticals 851
9.35 AstraZeneca 855
9.36 Attenuon 865
9.37 AVI BioPharma 867
9.38 Bavarian Nordic 869
9.39 Baxter International 871
9.40 Bayer 875
9.41 Bellicum Pharmaceuticals 880
9.42 Bioenvision 882
9.43 Biogen Idec 884
9.44 BioLineRx 887
9.45 BioMarin 889
9.46 BioNetWorks 892
9.47 BioSante 894
9.48 Biostar 896
9.49 Boehringer Ingelheim 899
9.50 Bristol-Myers Squibb 903
9.51 BTG 913
9.52 Camurus 916
9.53 Cancer Research Technology 920
9.54 Cel-Sci 926
9.55 Celgene 928
9.56 Cell Therapeutics 932
9.57 Celldex Therapeutics 936
9.58 Celsion 939
9.59 Center of Molecular Immunology 942
9.60 Cephalon 945
9.61 Chemokine Therapeutics 948
9.62 Circadian Technologies 951
9.63 Cleveland BioLabs 953
9.64 Colby 955
9.65 Cosmo Bioscience 959
9.66 Curaxis 962
9.67 Curis 966
9.68 Cylene Pharmaceuticals 968
9.69 Cytokinetics 972
9.70 Daiichi Sankyo 975
9.71 Debiopharm 979
9.72 Dendreon 984
9.73 Dongkook Pharm 988
9.74 ECI 993
9.75 Eisai 995
9.76 Eli Lilly 999
9.77 Endo Pharmaceuticals 1005
9.78 Endocyte 1009
9.79 Ensemble Discovery 1013
9.80 EntreMed 1015
9.81 EpiCept 1017
9.82 Esperance Pharmaceuticals 1020
9.83 Etubics 1024
9.84 EUSA Pharma 1027
9.85 Exelixis 1030
9.86 Ferring 1034
9.87 Formula Pharmaceuticals 1038
9.88 Galena Biopharma 1040
9.89 Gemin X Pharmaceuticals 1043
9.90 Generex 1046
9.91 GENova Biotherapeutics 1049
9.92 Genovax 1052
9.93 Genta 1055
9.94 Gerolymatos 1058
9.95 Geron 1062
9.96 Gilead Sciences 1066
9.97 GlaxoSmithKline 1069
9.98 GlycoGenesys 1073
9.99 Got-a-Gene 1075
9.100 GP Pharm 1079
9.101 Green Cross 1083
9.102 GTx 1085
9.103 Harbor BioSciences 1089
9.104 Hoffmann-La Roche 1092
9.105 Human Genome Sciences 1099
9.106 IGF Oncology 1101
9.107 Immunocore 1103
9.108 ImmunoGen 1105
9.109 Immunomedics 1108
9.110 ImmuPharma 1110
9.111 Incyte Corporation 1113
9.112 Infinity Pharmaceuticals 1115
9.113 Inovio 1117
9.114 Insmed 1121
9.115 Insys Therapeutics 1124
9.116 Introgen Therapeutics 1129
9.117 Ipsen 1131
9.118 Isis Pharmaceuticals 1135
9.119 Ivy Medical Chemicals 1138
9.120 Johnson & Johnson 1140
9.121 Karo Bio 1147
9.122 Kinex 1150
9.123 Kyowa Hakko Kirin 1152
9.124 Leo 1156
9.125 Ligand 1159
9.126 Lorus Therapeutics 1162
9.127 Mannkind 1164
9.128 Marillion Pharmaceuticals 1166
9.129 Med Discovery 1169
9.130 Meda 1171
9.131 Medarex 1176
9.132 MediGene 1179
9.133 MedImmune 1183
9.134 Mediolanum 1186
9.135 Medivation 1190
9.136 Menarini 1194
9.137 Merck & Co 1197
9.138 Merck KGaA 1202
9.139 Merrion Pharmaceuticals 1206
9.140 MethylGene 1210
9.141 Mojave Therapeutics 1212
9.142 Molecular Insight 1214
9.143 Nektar Therapeutics 1218
9.144 Nereus Pharmaceuticals 1222
9.145 Nerviano Medical Sciences 1224
9.146 Neurocrine Biosciences 1226
9.147 Nippon Shinyaku 1228
9.148 Non-industrial Sources 1231
9.149 Northwest Biotherapeutics 1235
9.150 Novacea 1238
9.151 Novartis 1241
9.152 Novogen 1250
9.153 Oasmia 1252
9.154 OncoGenex Pharmaceuticals 1255
9.155 Oncothyreon 1259
9.156 Oncovir 1261
9.157 Orion Pharma 1263
9.158 OSI Pharmaceuticals 1268
9.159 Oxford BioMedica 1272
9.160 Paladin Labs 1274
9.161 Pantarhei Bioscience 1277
9.162 Pepscan Therapeutics 1280
9.163 Pfizer 1283
9.164 Pharmacyclics 1289
9.165 PharmaGap 1291
9.166 PharmaMar 1293
9.167 Philogen 1296
9.168 Pierre Fabre 1298
9.169 Progen 1303
9.170 Progenics Pharmaceuticals 1305
9.171 ProNAi Therapeutics 1309
9.172 ProStrakan 1312
9.173 Q Chip 1315
9.174 QLT 1319
9.175 Receptor BioLogix 1323
9.176 Regeneron 1326
9.177 Regulon 1328
9.178 Rexahn 1330
9.179 Salzburg Therapeutics 1332
9.180 Samyang 1335
9.181 Sanofi 1338
9.182 Santaris Pharma 1348
9.183 Sapphire Therapeutics 1353
9.184 SBIO 1356
9.185 SeleXel 1359
9.186 Semafore Pharmaceuticals 1362
9.187 Serometrix 1364
9.188 SGX Pharmaceuticals 1367
9.189 Shire 1370
9.190 Siena Biotech 1375
9.191 Soligenix 1377
9.192 Sophiris Bio 1381
9.193 SRI International 1384
9.194 Supratek Pharma 1386
9.195 Switch Pharma 1389
9.196 Synta Pharmaceuticals 1391
9.197 Taiho 1393
9.198 Takeda 1395
9.199 Tapestry Pharmaceuticals 1400
9.200 Tau Therapeutics 1403
9.201 Teva 1406
9.202 Thallion Pharmaceuticals 1410
9.203 Therion Biologics 1412
9.204 Titan Pharmaceuticals 1414
9.205 Tokai Pharmaceuticals 1416
9.206 TopoTarget 1418
9.207 Tracon Pharmaceuticals 1421
9.208 Transgene 1423
9.209 Twinstrand Therapeutics 1425
9.210 Unigene 1428
9.211 United Biomedical 1432
9.212 Vaxon Biotech 1437
9.213 Velacor Therapeutics 1440
9.214 Vical 1442
9.215 Vion Pharmaceuticals 1445
9.216 VioQuest 1448
9.217 Viralytics 1451
9.218 ViroTarg 1453
9.219 VM Discovery 1455
9.220 Wilex 1458
9.221 Xerion 1460
9.222 Xoma 1464
9.223 YM BioSciences 1466
9.224 Zydus Cadila 1468
10 Disclaimer 1471
11 Drug Index 1472
12 Company Index 1484

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Prostate Cancer Drugs 373
Figure 2: The Drug-Target Competitive Landscape of Prostate Cancer Drugs - Larger Clusters 375
Figure 3: The Drug-Target Competitive Landscape Prostate Cancer Drugs - Smaller Clusters 376
Figure 4: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs – Larger Clusters 377
Figure 5: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs – Smaller Clusters 378
Figure 6: Distribution of Compound Strategies among Prostate Cancer Drugs 741
Figure 7: Primary Sub-cellular Localization of Drug Targets 742
Figure 8: Number of Companies per Ranking Level 759

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Prostate Cancer Drug Pipeline by Stage of Development 31
Table 3: Head to Head Target Competition among Prostate Cancer Drugs 31
Table 4: Overview of Drug Target Strategy Themes 36
Table 5: Terminally Ceased Targets of Prostate Cancer Drugs 37
Table 6: Official Gene Symbol to Target Profle 39
Table 7: Mutation Frequencies of Prostate Cancer Drug Targets 361
Table 8: Identity of Drug Targets with Available Biological Structures 366
Table 9: Number of Target-Target Interactions among Targets of Prostate Cancer Drugs 371
Table 10: Available Protein Expression Profiles of Prostate Cancer Drug Targets 379
Table 11: Pathway Summary 384
Table 12: Drug Targets without any Identified Assigned Pathways 384
Table 13: Pathway Profiles According to BioCarta of Prostate Cancer Drug Targets 386
Table 14: Pathway Profiles According to KEGG of Prostate Cancer Drug Targets 407
Table 15: Pathway Profiles According to NetPath of Prostate Cancer Drug Targets 430
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 438
Table 17: Top Competitive Target Strategies of Prostate Cancer Drugs 439
Table 18: New and Unique Target Strategies of Prostate Cancer Drugs in Pre-registration or on the Marketed 441
Table 19: The Competition Through Close Mechanistic Approximation Between Prostate Cancer Drugs Being Marketed 442
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Prostate Cancer Drugs 443
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Prostate Cancer Drugs 444
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Prostate Cancer Drugs 445
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Prostate Cancer Drugs 448
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Prostate Cancer Drugs 451
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Prostate Cancer Drugs 453
Table 26: New and Unique Target Strategies in Preclinical Development of Prostate Cancer Drugs 454
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Prostate Cancer Drugs 456
Table 28: Target Strategies of No Data, Suspended or Terminated Prostate Cancer Drugs 457
Table 29: Connecting Target Strategy with Its Profile Identification Number 461
Table 30: The Competition Through Close Mechanistic Approximation Among Prostate Cancer Drugs 690
Table 31: Overview of Compound Strategy Competition Among Prostate Cancer Drugs 701
Table 32: Overview of the Competitive Landscape of Small Molecule Based Prostate Cancer Drugs 703
Table 33: Competitive Comparison of Target Strategies of Small Molecule Prostate Cancer Drugs 704
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Prostate Cancer Drugs 710
Table 35: Overview of the Competitive Landscape of Peptide Based Prostate Cancer Drugs 718
Table 36: Competitive Comparison of Target Strategies of Peptide Based Prostate Cancer Drugs 719
Table 37: Pursued Target Strategies of Peptide Based Prostate Cancer Drugs 720
Table 38: Overview of the Competitive Landscape of Protein Based Prostate Cancer Drugs 722
Table 39: Competitive Comparison of Target Strategies of Protein Based Prostate Cancer Drugs 723
Table 40: Pursued Target Strategies of Protein Based Prostate Cancer Drugs 723
Table 41: Overview of the Competitive Landscape of Antibody Based Prostate Cancer Drugs 725
Table 42: Competitive Comparison of Target Strategies of Antibody Based Prostate Cancer Drugs 726
Table 43: Pursued Target Strategies of Antibody Based Prostate Cancer Drugs 727
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Prostate Cancer Drugs 730
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Prostate Cancer Drugs 731
Table 46: Pursued Target Strategies of Nucleic Acid Based Prostate Cancer Drugs 731
Table 47: Potential Forms of Cell Therapy 733
Table 48: Vectors in Gene Therapy 734
Table 49: Overview of the Competitive Landscape of Cell Therapy Based Prostate Cancer Drugs 734
Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Prostate Cancer Drugs 735
Table 51: Pursued Target Strategies of Cell Therapy Based Prostate Cancer Drugs 735
Table 52: Overview of the Competitive Landscape of Gene Therapy Based Prostate Cancer Drugs 736
Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Prostate Cancer Drugs 737
Table 54: Pursued Target Strategies of Gene Therapy Based Prostate Cancer Drugs 737
Table 55:Overview of the Competitive Landscape of Reformulated Prostate Cancer Drugs 738
Table 56: Competitive Comparison of Target Strategies of Reformulated Prostate Cancer Drugs 739
Table 57: Pursued Target Strategies of Reformulated Prostate Cancer Drugs 740
Table 58: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets 742
Table 59: Competitive Summary by Investigator of Prostate Cancer Drug Development 749
Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Prostate Cancer Drug Development 754
Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 758
Table 62: Example of a Competitive Fall-Out Table (Targeting TOP2A) 764
Table 63: Abbott’s Included Prostate Cancer Drugs and Competitive Fall-Out 769
Table 64: Active Biotech’s Included Prostate Cancer Drugs and Competitive Fall-Out 772
Table 65: Advantagene’s Included Prostate Cancer Drugs and Competitive Fall-Out 774
Table 66: AEgera’s Included Prostate Cancer Drugs and Competitive Fall-Out 776
Table 67: AEterna Zentaris’ Included Prostate Cancer Drugs and Competitive Fall-Out 778
Table 68: Alchemia’s Included Prostate Cancer Drugs and Competitive Fall-Out 781
Table 69: Alethia Biotherapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 783
Table 70: Allos Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 785
Table 71: AlphaVax’s Included Prostate Cancer Drugs and Competitive Fall-Out 787
Table 72: Alseres Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 791
Table 73: Altor BioScience’s Included Prostate Cancer Drugs and Competitive Fall-Out 793
Table 74: Ambrilia Biopharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 797
Table 75: American Gene Technology International’s Included Prostate Cancer Drugs and Competitive Fall-Out 800
Table 76: Amgen’s Included Prostate Cancer Drugs and Competitive Fall-Out 803
Table 77: Anavex Life Sciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 807
Table 78: AndroBioSys’ Included Prostate Cancer Drugs and Competitive Fall-Out 810
Table 79: Antisense Pharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 812
Table 80: Antisense Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 815
Table 81: Antisoma’s Included Prostate Cancer Drugs and Competitive Fall-Out 818
Table 82: Aphios’ Included Prostate Cancer Drugs and Competitive Fall-Out 822
Table 83: ApopLogic Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 824
Table 84: Apotex’s Included Prostate Cancer Drugs and Competitive Fall-Out 826
Table 85: Aprea’s Included Prostate Cancer Drugs and Competitive Fall-Out 828
Table 86: Ardana’s Included Prostate Cancer Drugs and Competitive Fall-Out 832
Table 87: Ariad’s Included Prostate Cancer Drugs and Competitive Fall-Out 836
Table 88: ArQule’s Included Prostate Cancer Drugs and Competitive Fall-Out 838
Table 89: Array BioPharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 840
Table 90: Ascenta Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 842
Table 91: Ascepion Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 844
Table 92: Astellas’ Included Prostate Cancer Drugs and Competitive Fall-Out 848
Table 93: Astex Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 853
Table 94: AstraZeneca’s Included Prostate Cancer Drugs and Competitive Fall-Out 859
Table 95: Attenuon’s Included Prostate Cancer Drugs and Competitive Fall-Out 866
Table 96: AVI BioPharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 868
Table 97: Bavarian Nordic’s Included Prostate Cancer Drugs and Competitive Fall-Out 870
Table 98: Baxter International’s Included Prostate Cancer Drugs and Competitive Fall-Out 874
Table 99: Bayer’s Included Prostate Cancer Drugs and Competitive Fall-Out 877
Table 100: Bellicum Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 881
Table 101: Bioenvision’s Included Prostate Cancer Drugs and Competitive Fall-Out 883
Table 102: Biogen Idec’s Included Prostate Cancer Drugs and Competitive Fall-Out 886
Table 103: BioLineRx’s Included Prostate Cancer Drugs and Competitive Fall-Out 888
Table 104: BioMarin’s Included Prostate Cancer Drugs and Competitive Fall-Out 891
Table 105: BioNetWorks’ Included Prostate Cancer Drugs and Competitive Fall-Out 893
Table 106: BioSante’s Included Prostate Cancer Drugs and Competitive Fall-Out 895
Table 107: Biostar’s Included Prostate Cancer Drugs and Competitive Fall-Out 898
Table 108: Boehringer Ingelheim’s Included Prostate Cancer Drugs and Competitive Fall-Out 901
Table 109: Bristol-Myers Squibb’s Included Prostate Cancer Drugs and Competitive Fall-Out 907
Table 110: BTG’s Included Prostate Cancer Drugs and Competitive Fall-Out 915
Table 111: Camurus’ Included Prostate Cancer Drugs and Competitive Fall-Out 919
Table 112: Cancer Research Technology’s Included Prostate Cancer Drugs and Competitive Fall-Out 923
Table 113: Cel-Sci’s Included Prostate Cancer Drugs and Competitive Fall-Out 927
Table 114: Celgene’s Included Prostate Cancer Drugs and Competitive Fall-Out 930
Table 115: Cell Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 934
Table 116: Celldex Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 938
Table 117: Celsion’s Included Prostate Cancer Drugs and Competitive Fall-Out 941
Table 118: Center of Molecular Immunology’s Included Prostate Cancer Drugs and Competitive Fall-Out 944
Table 119: Cephalon’s Included Prostate Cancer Drugs and Competitive Fall-Out 947
Table 120: Chemokine Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 950
Table 121: Circadian Technologies’ Included Prostate Cancer Drugs and Competitive Fall-Out 952
Table 122: Cleveland BioLabs’ Included Prostate Cancer Drugs and Competitive Fall-Out 954
Table 123: Colby’s Included Prostate Cancer Drugs and Competitive Fall-Out 957
Table 124: Cosmo Bioscience’s Included Prostate Cancer Drugs and Competitive Fall-Out 961
Table 125: Curaxis’ Included Prostate Cancer Drugs and Competitive Fall-Out 965
Table 126: Curis’ Included Prostate Cancer Drugs and Competitive Fall-Out 967
Table 127: Cylene Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 970
Table 128: Cytokinetics’ Included Prostate Cancer Drugs and Competitive Fall-Out 974
Table 129: Daiichi Sankyo’s Included Prostate Cancer Drugs and Competitive Fall-Out 977
Table 130: Debiopharm’s Included Prostate Cancer Drugs and Competitive Fall-Out 982
Table 131: Dendreon’s Included Prostate Cancer Drugs and Competitive Fall-Out 986
Table 132: Dongkook Pharm’s Included Prostate Cancer Drugs and Competitive Fall-Out 991
Table 133: ECI’s Included Prostate Cancer Drugs and Competitive Fall-Out 994
Table 134: Eisai’s Included Prostate Cancer Drugs and Competitive Fall-Out 997
Table 135: Eli Lilly’s Included Prostate Cancer Drugs and Competitive Fall-Out 1001
Table 136: Endo Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1008
Table 137: Endocyte’s Included Prostate Cancer Drugs and Competitive Fall-Out 1011
Table 138: Ensemble Discovery’s Included Prostate Cancer Drugs and Competitive Fall-Out 1014
Table 139: EntreMed’s Included Prostate Cancer Drugs and Competitive Fall-Out 1016
Table 140: EpiCept’s Included Prostate Cancer Drugs and Competitive Fall-Out 1019
Table 141: Esperance Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1022
Table 142: Etubics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1026
Table 143: EUSA Pharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1029
Table 144: Exelixis’ Included Prostate Cancer Drugs and Competitive Fall-Out 1032
Table 145: Ferring’s Included Prostate Cancer Drugs and Competitive Fall-Out 1037
Table 146: Formula Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1039
Table 147: Galena Biopharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1042
Table 148: Gemin X Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1045
Table 149: Generex’s Included Prostate Cancer Drugs and Competitive Fall-Out 1048
Table 150: GENova Biotherapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1051
Table 151: Genovax’s Included Prostate Cancer Drugs and Competitive Fall-Out 1054
Table 152: Genta’s Included Prostate Cancer Drugs and Competitive Fall-Out 1057
Table 153: Gerolymatos’ Included Prostate Cancer Drugs and Competitive Fall-Out 1060
Table 154: Geron’s Included Prostate Cancer Drugs and Competitive Fall-Out 1064
Table 155: Gilead Sciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 1068
Table 156: GlaxoSmithKline’s Included Prostate Cancer Drugs and Competitive Fall-Out 1071
Table 157: GlycoGenesys’ Included Prostate Cancer Drugs and Competitive Fall-Out 1074
Table 158: Got-a-Gene’s Included Prostate Cancer Drugs and Competitive Fall-Out 1077
Table 159: GP Pharm’s Included Prostate Cancer Drugs and Competitive Fall-Out 1082
Table 160: Green Cross’ Included Prostate Cancer Drugs and Competitive Fall-Out 1084
Table 161: GTx’s Included Prostate Cancer Drugs and Competitive Fall-Out 1087
Table 162: Harbor BioSciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 1091
Table 163: Hoffmann-La Roche’s Included Prostate Cancer Drugs and Competitive Fall-Out 1095
Table 164: Human Genome Sciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 1100
Table 165: IGF Oncology’s Included Prostate Cancer Drugs and Competitive Fall-Out 1102
Table 166: Immunocore’s Included Prostate Cancer Drugs and Competitive Fall-Out 1104
Table 167: ImmunoGen’s Included Prostate Cancer Drugs and Competitive Fall-Out 1107
Table 168: Immunomedics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1109
Table 169: ImmuPharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1112
Table 170: Incyte Corporation’s Included Prostate Cancer Drugs and Competitive Fall-Out 1114
Table 171: Infinity Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1116
Table 172: Inovio’s Included Prostate Cancer Drugs and Competitive Fall-Out 1119
Table 173: Insmed’s Included Prostate Cancer Drugs and Competitive Fall-Out 1123
Table 174: Insys Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1127
Table 175: Introgen Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1130
Table 176: Ipsen’s Included Prostate Cancer Drugs and Competitive Fall-Out 1133
Table 177: Isis Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1136
Table 178: Ivy Medical Chemicals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1139
Table 179: Johnson & Johnson’s Included Prostate Cancer Drugs and Competitive Fall-Out 1143
Table 180: Karo Bio’s Included Prostate Cancer Drugs and Competitive Fall-Out 1149
Table 181: Kinex’s Included Prostate Cancer Drugs and Competitive Fall-Out 1151
Table 182: Kyowa Hakko Kirin’s Included Prostate Cancer Drugs and Competitive Fall-Out 1154
Table 183: Leo’s Included Prostate Cancer Drugs and Competitive Fall-Out 1158
Table 184: Ligand’s Included Prostate Cancer Drugs and Competitive Fall-Out 1161
Table 185: Lorus Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1163
Table 186: Mannkind’s Included Prostate Cancer Drugs and Competitive Fall-Out 1165
Table 187: Marillion Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1168
Table 188: Med Discovery’s Included Prostate Cancer Drugs and Competitive Fall-Out 1170
Table 189: Meda’s Included Prostate Cancer Drugs and Competitive Fall-Out 1174
Table 190: Medarex’s Included Prostate Cancer Drugs and Competitive Fall-Out 1178
Table 191: MediGene’s Included Prostate Cancer Drugs and Competitive Fall-Out 1181
Table 192: MedImmune’s Included Prostate Cancer Drugs and Competitive Fall-Out 1185
Table 193: Mediolanum’s Included Prostate Cancer Drugs and Competitive Fall-Out 1189
Table 194: Medivation’s Included Prostate Cancer Drugs and Competitive Fall-Out 1192
Table 195: Menarini’s Included Prostate Cancer Drugs and Competitive Fall-Out 1196
Table 196: Merck & Co’s Included Prostate Cancer Drugs and Competitive Fall-Out 1200
Table 197: Merck KGaA’s Included Prostate Cancer Drugs and Competitive Fall-Out 1204
Table 198: Merrion Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1209
Table 199: MethylGene’s Included Prostate Cancer Drugs and Competitive Fall-Out 1211
Table 200: Mojave Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1213
Table 201: Molecular Insight’s Included Prostate Cancer Drugs and Competitive Fall-Out 1216
Table 202: Nektar Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1221
Table 203: Nereus Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1223
Table 204: Nerviano Medical Sciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 1225
Table 205: Neurocrine Biosciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 1227
Table 206: Nippon Shinyaku’s Included Prostate Cancer Drugs and Competitive Fall-Out 1229
Table 207: Non-industrial source’s Included Prostate Cancer Drugs and Competitive Fall-Out 1233
Table 208: Northwest Biotherapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1237
Table 209: Novacea’s Included Prostate Cancer Drugs and Competitive Fall-Out 1240
Table 210: Novartis’ Included Prostate Cancer Drugs and Competitive Fall-Out 1244
Table 211: Novogen’s Included Prostate Cancer Drugs and Competitive Fall-Out 1251
Table 212: Oasmia’s Included Prostate Cancer Drugs and Competitive Fall-Out 1254
Table 213: OncoGenex Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1257
Table 214: Oncothyreon’s Included Prostate Cancer Drugs and Competitive Fall-Out 1260
Table 215: Oncovir’s Included Prostate Cancer Drugs and Competitive Fall-Out 1262
Table 216: Orion Pharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1266
Table 217: OSI Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1270
Table 218: Oxford BioMedica’s Included Prostate Cancer Drugs and Competitive Fall-Out 1273
Table 219: Paladin Labs’ Included Prostate Cancer Drugs and Competitive Fall-Out 1276
Table 220: Pantarhei Bioscience’s Included Prostate Cancer Drugs and Competitive Fall-Out 1279
Table 221: Pepscan Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1282
Table 222: Pfizer’s Included Prostate Cancer Drugs and Competitive Fall-Out 1285
Table 223: Pharmacyclics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1290
Table 224: PharmaGap’s Included Prostate Cancer Drugs and Competitive Fall-Out 1292
Table 225: PharmaMar’s Included Prostate Cancer Drugs and Competitive Fall-Out 1294
Table 226: Philogen’s Included Prostate Cancer Drugs and Competitive Fall-Out 1297
Table 227: Pierre Fabre’s Included Prostate Cancer Drugs and Competitive Fall-Out 1301
Table 228: Progen’s Included Prostate Cancer Drugs and Competitive Fall-Out 1304
Table 229: Progenics Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1307
Table 230: ProNAi Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1311
Table 231: ProStrakan’s Included Prostate Cancer Drugs and Competitive Fall-Out 1314
Table 232: Q Chip’s Included Prostate Cancer Drugs and Competitive Fall-Out 1318
Table 233: QLT’s Included Prostate Cancer Drugs and Competitive Fall-Out 1322
Table 234: Receptor BioLogix’s Included Prostate Cancer Drugs and Competitive Fall-Out 1325
Table 235: Regeneron’s Included Prostate Cancer Drugs and Competitive Fall-Out 1327
Table 236: Regulon’s Included Prostate Cancer Drugs and Competitive Fall-Out 1329
Table 237: Rexahn’s Included Prostate Cancer Drugs and Competitive Fall-Out 1331
Table 238: Salzburg Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1334
Table 239: Samyang’s Included Prostate Cancer Drugs and Competitive Fall-Out 1337
Table 240: Sanofi’s Included Prostate Cancer Drugs and Competitive Fall-Out 1343
Table 241: Santaris Pharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1351
Table 242: Sapphire Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1355
Table 243: SBIO’s Included Prostate Cancer Drugs and Competitive Fall-Out 1358
Table 244: SeleXel’s Included Prostate Cancer Drugs and Competitive Fall-Out 1361
Table 245: Semafore Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1363
Table 246: Serometrix’s Included Prostate Cancer Drugs and Competitive Fall-Out 1366
Table 247: SGX Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1369
Table 248: Shire’s Included Prostate Cancer Drugs and Competitive Fall-Out 1373
Table 249: Siena Biotech’s Included Prostate Cancer Drugs and Competitive Fall-Out 1376
Table 250: Soligenix’s Included Prostate Cancer Drugs and Competitive Fall-Out 1380
Table 251: Sophiris Bio’s Included Prostate Cancer Drugs and Competitive Fall-Out 1383
Table 252: SRI International’s Included Prostate Cancer Drugs and Competitive Fall-Out 1385
Table 253: Supratek Pharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1388
Table 254: Switch Pharma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1390
Table 255: Synta Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1392
Table 256: Taiho’s Included Prostate Cancer Drugs and Competitive Fall-Out 1394
Table 257: Takeda’s Included Prostate Cancer Drugs and Competitive Fall-Out 1397
Table 258: Tapestry Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1402
Table 259: Tau Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1404
Table 260: Teva’s Included Prostate Cancer Drugs and Competitive Fall-Out 1408
Table 261: Thallion Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1411
Table 262: Therion Biologics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1413
Table 263: Titan Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1415
Table 264: Tokai Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1417
Table 265: TopoTarget’s Included Prostate Cancer Drugs and Competitive Fall-Out 1420
Table 266: Tracon Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1422
Table 267: Transgene’s Included Prostate Cancer Drugs and Competitive Fall-Out 1424
Table 268: Twinstrand Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1427
Table 269: Unigene’s Included Prostate Cancer Drugs and Competitive Fall-Out 1431
Table 270: United Biomedical’s Included Prostate Cancer Drugs and Competitive Fall-Out 1435
Table 271: Vaxon Biotech’s Included Prostate Cancer Drugs and Competitive Fall-Out 1439
Table 272: Velacor Therapeutics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1441
Table 273: Vical’s Included Prostate Cancer Drugs and Competitive Fall-Out 1444
Table 274: Vion Pharmaceuticals’ Included Prostate Cancer Drugs and Competitive Fall-Out 1447
Table 275: VioQuest’s Included Prostate Cancer Drugs and Competitive Fall-Out 1449
Table 276: Viralytics’ Included Prostate Cancer Drugs and Competitive Fall-Out 1452
Table 277: ViroTarg’s Included Prostate Cancer Drugs and Competitive Fall-Out 1454
Table 278: VM Discovery’s Included Prostate Cancer Drugs and Competitive Fall-Out 1457
Table 279: Wilex’s Included Prostate Cancer Drugs and Competitive Fall-Out 1459
Table 280: Xerion’s Included Prostate Cancer Drugs and Competitive Fall-Out 1462
Table 281: Xoma’s Included Prostate Cancer Drugs and Competitive Fall-Out 1465
Table 282: YM BioSciences’ Included Prostate Cancer Drugs and Competitive Fall-Out 1467
Table 283: Zydus Cadila’s Included Prostate Cancer Drugs and Competitive Fall-Out 1470

This report includes 222 companies (Incl. Active, Out of Business and M&A) plus their collaborators:
Abbott
Active Biotech
Advantagene
AEgera
AEterna Zentaris
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bioenvision
Biogen Idec
BioLineRx
BioMarin
BioNetWorks
BioSante
Biostar
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
Cancer Research Technology
Celgene
Cell Therapeutics
Celldex Therapeutics
Cel-Sci
Celsion
Center of Molecular Immunology
Cephalon
Chemokine Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
Cosmo Bioscience
Curaxis
Curis
Cylene Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Debiopharm
Dendreon
Dongkook Pharm
ECI
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Formula Pharmaceuticals
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
IGF Oncology
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Inovio
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Ivy Medical Chemicals
Johnson & Johnson
Karo Bio
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Mojave Therapeutics
Molecular Insight
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
Oasmia
OncoGenex Pharmaceuticals
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Philogen
Pierre Fabre
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Q Chip
QLT
Receptor BioLogix
Regeneron
Regulon
Rexahn
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
SBIO
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Soligenix
Sophiris Bio
SRI International
Supratek Pharma
Switch Pharma
Synta Pharmaceuticals
Taiho
Takeda
Tapestry Pharmaceuticals
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Twinstrand Therapeutics
Unigene
United Biomedical
Vaxon Biotech
Velacor Therapeutics
Vical
Vion Pharmaceuticals
VioQuest
Viralytics
ViroTarg
VM Discovery
Wilex
Xerion
Xoma
YM BioSciences
Zydus Cadila
This report includes 394 prostate cancer drugs. From Ceased to Marketed. Some examples are:
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEZS-108
afatinib
aflibercept
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
APC-100
APR-246
ARC-100
atrasentan
AVX-701
bafetinib
bevacizumab
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
buserelin
Cabozantinib
carlumab
cediranib
celecoxib
cetuximab
cixutumumab
custirsen
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
entinostat
enzastaurin hydrochloride
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fulvestrant
gataparsen
GDC-0980
gefitinib
goserelin (1)
GTx-758
GVAX
GVX-3322
GX-301
HE-3235
histrelin
idronoxil
imatinib mesilate
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
irosustat
ispinesib mesylate
KX2-391
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
MLN-8237
Nab-docetaxel
nadroparin
nilutamide
nimotuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
orteronel
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
perifosine
pertuzumab
plitidepsin
PLX-3397
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
retaspimycin
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sorafenib tosylate
TAK-448
tandutinib
tasquinimod
telomerase vaccine
temsirolimus
Tenarad
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Competitive Handbook towards Personalized Medicine in Prostate Cancer.
    To find out more about Competitive Handbook towards Personalized Medicine in Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Competitive Handbook towards Personalized Medicine in Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Vascular Targeting Agents: Emerging Competitors
An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More


A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Leukemia and Lymphoma
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Lymphoma. Learn More


Decoding Big Pharmas R&D Strategy in Oncology
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Learn More